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ABSTRACT 
Five biologicals have been approved for severe eosinophilic asthma, a well-recognised 
phenotype.  Systematic reviews (SR) evaluated the efficacy and safety of benralizumab, 
dupilumab, mepolizumab, omalizumab and reslizumab (alphabetical order) compared to standard 
of care for severe eosinophilic asthma. 
Pubmed, EMBASE and Cochrane Library were searched to identify RCTs and health economic 
evaluations, published in English. Critical and important asthma-related outcomes were evaluated 
for each of the biologicals. The risk of bias and the certainty of the evidence were assessed using 
GRADE. 
19 RCTs (3 RCTs for benralizumab, 3 RCTs for dupilumab, 3 RCTs for mepolizumab, 4 RCTs for 
omalizumab, and 5 RCTs for reslizumab), including subjects 12 to 75 years old (except for 
omalizumab including also subjects 6-11 years old), ranging from 12 to 56 weeks were evaluated. 
All biologicals reduce exacerbation rates with high certainty of evidence: benralizumab rate ratio 
(RR) 0.53 (95% CI 0.39 to 0.72), dupilumab RR 0.43 (95% CI 0.32 to 0.59), mepolizumab RR 
0.49 (95% CI 0.38 to 0.66), omalizumab RR 0.56 (95% CI 0.40 to 0.77), and reslizumab RR 0.46 
(95% CI 0.37 to 0.58). Benralizumab, dupilumab and mepolizumab reduce the daily dose of oral 
corticosteroids (OCS) with high certainty of evidence. All evaluated biologicals probably improve 
asthma control, QoL and FEV1, without reaching the minimal important difference (moderate 
certainty). Benralizumab, mepolizumab and reslizumab slightly increase drug-related adverse 
events (AE) and drug-related serious AE (low to very low certainty of evidence). The incremental 
cost-effectiveness ratio per quality adjusted life-years value is above the willingness to pay 
threshold for all biologicals (moderate certainty). Potential savings are driven by decrease in 
hospitalisations, emergency and primary care visits. 
There is high certainty that all approved biologicals reduce the rate of severe asthma 
exacerbations and for benralizumab, dupilumab and mepolizumab for reducing OCS. There is 
moderate certainty for improving asthma control, QoL, FEV1 and cost-effectiveness. More data on 
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MD = mean difference
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QoL = quality of life
RCT = randomised controlled trial
ROB = risk of bias 
SGRQ = St George’s Respiratory Questionnaire
SOC= standard of care
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Introduction
There are still a significant proportion of patients with severe asthma having uncontrolled 
or partially controlled asthma despite correct management. These patients represent a special 
challenge related to extensive diagnostic evaluation and high consumption of health-care 
resources (1,2,3,4). Severe asthma is defined as inadequate control of asthma under high-
intensity treatment with inhaled corticosteroids (ICS) and additional controllers (including oral 
corticosteroid (OCS)) for at least six months per year, or by loss of asthma control on the attempt 
to reduce the high-intensity treatment (5). Before any further treatments are evaluated, differential 
diagnoses of asthma should be ruled out, comorbidities should be treated, persistent triggers 
should be eliminated, and patient adherence should be optimised (2,5,6). Considering the 
availability of specific targeted therapies for type 2 (T2) asthma, the management approach to 
severe asthma currently includes a phenotyping step for the identification of allergic, eosinophilic 
and non-T2 phenotypes (7,8).
Eosinophils are prominent pathogenic cells involved in asthma. Increased blood or sputum 
eosinophils were related to frequent asthma exacerbations and disease severity and are used to 
guide treatment decisions (9,10,11).  Most human diseases accompanied by elevated blood 
eosinophils are associated with increased interleukin (IL)-5 production. Although IL-5 plays a 
central role in eosinophil biology, it is neither necessary nor sufficient for fully inducing an 
eosinophil mediated disease. In humans, IL-5 is often co-expressed with other T2 cytokines 
including IL-4 and IL-13 and associated in atopic individuals with increased immunoglobulin (Ig)-E 
production (12,13,14,15,16). This over-lap between the key pathogenetic pathways (IL-5, IL-4/IL-
13 and IgE driven eosinophilic inflammation) toughen the choice of a biological for the 
eosinophilic asthma phenotype. Therefore, future novel approaches to better identify predominant 
pathways at the molecular level (endotypes) are demanded.
In the last decades, new add-on therapies for severe asthma have been developed, and 
may be applied depending on asthma phenotype and endotype (7, 8, 13). Anti-IL-5 monoclonal 
antibodies (mepolizumab and reslizumab) are approved for severe asthma and peripheral 
eosinophilia (17,18,19,20). Benralizumab, a monoclonal antibody that binds to the α subunit of IL-
5 receptor (IL-5Rα) was also recently approved for eosinophilic asthma (21,22). Dupilumab, a 
monoclonal antibody directed against the α subunit of the IL-4 receptor (IL-4Rα) acting as a dual 
inhibitor of both IL-4- and IL-13-mediated signalling pathways was approved for T2 asthma 
(23,24). Omalizumab, a humanised monoclonal anti-IgE antibody, was the first biological 
approved for IgE-mediated persistent allergic asthma (25,26). 
The European Academy of Allergy and Clinical Immunology (EAACI) is developing clinical 
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systematic reviews (SR) were performed to inform the formulation of key clinical 
recommendations. The current SR is focusing on eosinophilic asthma assessing the current 
evidence regarding efficacy, safety and economic impact of the biologicals with current regulatory 
approval for patients with uncontrolled severe asthma (i.e. benralizumab, dupilumab, 










This article is protected by copyright. All rights reserved
METHODS 
Guideline Development Group
The EAACI Asthma Voting Panel and Guidelines Steering Committee includes clinicians and 
researchers with different backgrounds (the complete list of experts is available from the EAACI 
website) whom voluntarily participate in the development of EAACI clinical practice guidelines for 
the use biologicals in severe asthma. They are referred to as the Guideline Development Group 
(GDG).
Structured question and outcome prioritisation
The GDG framed the clinical question as: “Is the treatment with biologicals (i.e., benralizumab, 
dupilumab, mepolizumab, omalizumab and reslizumab) efficacious and safe for patients with 
uncontrolled severe eosinophilic asthma?” For the purpose of this SR the population of interest 
was defined as subjects with any of the following: a sputum eosinophil count of ≥1% or an 
asthma-related peripheral blood eosinophil count of ≥150 cells/ μL, or a fractional exhaled nitric 
oxide (FeNO) of ≥20 ppb (27). The outcomes were prioritised by the GDG using a 1 to 9 scale (7 
to 9 critical; 4 to 6 important; 1 to 3 of limited importance), as suggested by the GRADE 
approach. The critical outcomes were exacerbations, asthma control, QoL, and safety and the 
important outcomes included lung function (forced expiratory volume in one second – FEV1), 
OCS and ICS use and rescue medication use (table S1). Safety was assessed evaluating the 
rate of drug-related adverse events (AE) or drug-related serious AEs.
The GDG also framed a cost-effectiveness question to assess the economic impact of these 
biologicals versus standard of care for patients with uncontrolled severe eosinophilic asthma. The 
outcomes of interest were costs and resource use, as well as the incremental cost-effectiveness 
ratios (ICERs) per both quality adjusted life-years (QALY) and per asthma-specific outcomes. 
Data sources and searches
MEDLINE (via PubMed, January 2019), EMBASE (via Ovid, January 2019) and CENTRAL (via 
The Cochrane Library, January 2019) databases were searched using pre-defined algorithms for 
individual studies for evidence of effects and economic evaluations, including systematic reviews 
as source of individual studies. Search terms were adapted to each database, validated filters 
were used to retrieve appropriate designs. Members of the GDG were requested to provide 
additional studies for evaluation (Table S2).  
Study selection
Randomised controlled trials (RCTs) of patients with uncontrolled severe eosinophilic asthma that 
compared benralizumab, dupilumab, mepolizumab, omalizumab or reslizumab versus standard of 
care were included in the SR. Separate searches for each of the five biologicals evaluated were 
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approved by the European Medical Agency (EMA) or by U.S. Food and Drug administration 
(FDA). Abstracts or conference communications not published as full articles in peer reviewed 
journals were also excluded. Only studies published in English were considered. Two reviewers 
independently assessed the references based on tittle and abstract. Then, two reviewers 
independently assessed the eligibility of the studies according to inclusion criteria. Discrepancies 
were solved either by consensus or with the help of a third reviewer. All citations retrieved were 
imported into the bibliographic reference software (EndNote X5; Thomson Reuters) to discard 
duplicates and record screening decisions. 
Data extraction and risk of bias assessment
Details of the study design, patient population, setting, follow-up, and results were extracted by 
one reviewer, and confirmed by a second reviewer. If needed, requested additional data from the 
authors of the included studies was requested. The risk of bias (ROB) was assessed using the 
Cochrane Risk of Bias Assessment tool (28). The ROB was judged as low, high or unclear risk 
the for each domain: random sequence generation, allocation concealment, blinding of 
participants and personnel, blinding of outcome assessment, incomplete outcome data, and 
selective reporting.
For the health economics analysis, two reviewers extracted the main characteristics of included 
studies (e.g. type of economic evaluation, perspective, time horizon, discounting, sources of 
information, model type), relevant outcomes and costs (e.g. ICERs, sensitivity analyses results), 
sources of funding, and conflict of interest. Two reviewers assessed the methodological 
limitations using the consensus on health economics criteria (CHEC) checklist (29). 
Transferability to the European context was assessed using the European Network of Health 
Economic Evaluation Databases (EURONHEED) checklist (30,31). 
Data synthesis and analysis
The main results of the SR are described narratively and tabulated as summary of findings. For 
dichotomous variables data were pooled as incidence rate ratios (IRR) and risk ratios (RR). For 
continuous data mean differences, with 95% confidence intervals were used. Change in the 
observed asthma related outcomes were assessed between biologicals and placebo from 
baseline to the end of the treatment. A random-effects model was used to pool data (Review 
Manager V5.3). Where multiple arms were compared to a common placebo arm standard errors 
were adjusted to avoid the unit of analysis error (32).  
Statistical heterogeneity beyween studies was assessed using the Cochrane chi-square test, and 
the magnitude of heterogeneity with the I2 statistic. To account for clinical heterogeneity, the 
analyses were stratified whenever possible by different doses of the biological, age, relevant 
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baseline use of OCS was performed. To estimate the absolute effects for each comparison the 
median estimate reported in the control arms was used as baseline risk. For the economic 
evidence, results are summarised narratively and tabulated, including the ICERs and the degree 
of uncertainty. 
Certainty of evidence
The certainty (quality) of the evidence of efficacy, safety and economic impact for each outcome 
was rated as high, moderate, low or very low considering the standard GRADE domains: ROB, 
imprecision, inconsistency, indirectness and publication bias (33,34). For the evaluation of 
imprecision for each asthma related outcome evaluated, where available, the minimal important 
difference (MID) thresholds were considered (35, 36,37, 38). For FEV1, a MID of 0.20 L was 
considered as recommended by consensus by the GDG.   
RESULTS
Search results 
The eligibility process is summarized in a PRISMA flowchart (Figure 1). A total of 3441 unique 
citations were retrieved from data base searches, and 145 were appraised as full text. 135 
publications were excluded due to differences in population, outcomes of interest, design or 
regulatory unapproved dose and/or route (Table S3). 28 publications from 19 RCTs were 
evaluate. These included 3 RCTs for benralizumab (39,40,41); 3 for dupilumab (42,43,44); 3 for 
mepolizumab (45,46,47); 4 for omalizumab (48,49,50,51); and 5 for reslizumab (52,53,54,55). 
Characteristic of included studies
The characteristics of studies evaluated for evidence of efficacy and safety are detailed in Table 
1. All studies randomised to either an intervention arm or a standard of care/placebo arm. All 
were RCTs, conducted during the previous eight years (2011-2019). The follow up under study 
medication ranged from 12 to 56 weeks.  All studies included subjects aged 12 to 75 years old 
and studies of omalizumab also included children from 6 years old. The characteristics of the 
health economics studies included are available in Table 2. 
Evidence of efficacy and safety
Tables 3 to 7 present the summary of the results and certainty of evidence for asthma related 
outcomes evaluated. The metanalysis plots can be found in the supplementary file.
Severe asthma exacerbation rate
The annualized exacerbation rates were reported in 3 benralizumab trials (39,40,41); 3 dupilumab 
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reslizumab trials (52,53,54,55). All biologicals reduced asthma exacerbations rate compared to 
standard of care with high certainty of evidence: benralizumab RR 0.53; 95% CI 0.39 to 0.72; 
dupilumab RR 0.44; 95% CI 0.32 to 0.59; mepolizumab RR 0.49 95% CI 0.38 to 0.66; 
omalizumab RR 0.56; 95% CI 0.40 to 0.77; and reslizumab RR 0.46; 95% CI 0.37 to 0.58.
A separate analysis of the studies (41,44,46) designed to assess as primary outcome the OCS 
sparing effect of the biological compared to standard of care was performed. All three studies 
significantly reduced the rate of exacerbations in the OCS sparing protocol with high certainty of 
evidence: benralizumab RR 0.30; 95% CI 0.17 to 0.53; dupilumab RR 0.42; 95%CI 0.25 to 0.69; 
and mepolizumab RR 0.68; 95%CI 0.47 to 0.98.
Asthma control
The change in asthma control following biologicals addition was evaluated using Asthma Control 
Questionnaires (ACQ) scores and the Total Asthma Symptoms Scores (TASS). Dupilumab, 
omalizumab and mepolizumab probably improve asthma control with moderate certainty of 
evidence: dupilumab (ACQ-5) MD -0.48; 95% -0.88 to -0.09 (42,43,44); omalizumab (TASS) MD -
0.16; 95% -0.51 to 0.19 (48,49,50,51) and mepolizumab (ACQ-5) MD -0.43; 95% CI -0.56 to -
0.31 (45,46,47). Nevertheless, none of the biologicals showed an improvement above the MID 
threshold of 0.5.
Quality of life
QoL was reported in 3 benralizumab trials (39,40,41); 2 dupilumab trials (42,43); 3 mepolizumab 
trials (45,46,47); 1 omalizumab trial (48) and 3 reslizumab trials (53, 54, 55).  Changes in QoL 
were evaluated using the Asthma Quality of Life Questionnaire (AQLQ) for all biologicals, except 
for mepolizumab that used the St. George's Respiratory Questionnaire (SGRQ) score. All The 
addition of all biologicals improved QoL with moderate to high certainty, although below the MID: 
benralizumab MD +0.23 (95% CI 0.11 to 0.36); dupilumab MD +0.42 (95% CI +0.25 to +0.59); 
mepolizumab (SGRQ) MD -7.14 (95% CI -9.07 to -5.21); omalizumab MD +0.13 (95% CI +0.11 to 
+0.37); and reslizumab MD +0.17 (95% CI +0.08 to +0.25). 
Safety
Drug-related AE were assessed in 2 trials for benralizumab (40,41), 1 trial for dupilumab (42), 3 
mepolizumab trials (45,46,47), 1 trial for omalizumab (48) and 3 trials for reslizumab (52,53,55). 
For mepolizumab there is an increased likelihood of drug-related AE (RR 1.35; 95% CI 1.01 to 
1.80; high certainty of evidence. Benralizumab and reslizumab probably increases drug-related 
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1.18, 95% CI 0.89 to 1.56. For dupilumab and omalizumab the RR is rather small: dupilumab RR 
of 1.00, 95% CI 0.88 to 1.13; omalizumab RR 1.01, 95% CI 0.91 to 1.1.
There is low to very low certainty of evidence that drug-related serious AE may increase with the 
use of dupilumab RR 1.46 (95% 0.60 to 3.54) and reslizumab RR 4.71 (95% 0.54 to 41.31). For 
benralizumab and mepolizumab results are inconclusive: benralizumab RR 0.56 (95% CI 0.22 to 
1.44); mepolizumab RR 0.98 (95% CI 0.06 to 15.63). Data were not fully reported in all trials thus 
the certainty of evidence was downgraded due to the low number of events.
Reduction of oral corticosteroids use 
Benralizumab, dupilumab and mepolizumab showed with high certainty of evidence a reduction in 
daily OCS: benralizumab > 50% (RR 1.76, 95%CI 1.26 to 2.47; dupilumab 29.4% (95% CI 43.2 
lower to 15.57 lower); and mepolizumab > 50% (RR 1.61; 95%CI 1.07-2.41) (41,44,46). 
Mepolizumab showed a reduction of OCS to 5mg/day or less (crude RR 1.71; 95%CI 1.11 to 
2.55, p=0.01) and a reduction of 100% in daily OCS (crude RR 1.91; 95% CI 0.69 to 5.30, p=0.2) 
compared to placebo.
Reduction of rescue medication use
This end-point was assessed only for mepolizumab and showed no clinically significant reduction 
in the daily use of rescue medication after 24 weeks (MD - 0.1 puffs /day; CI 95% -0.35 to 0.15) 
(45).  
Lung function - FEV1 
The change from baseline of FEV1 were assessed for benralizumab (39,40,41), mepolizumab 
(45,46,47), omalizumab (48) and reslizumab (52,53,54,55). Compared to standard of care, there 
was an increase of FEV1, but below the MID agreed by the GDG (moderate certainty of evidence):  
benralizumab MD +140mL (95% CI +90 to +190); mepolizumab MD +110.9 mL (95% CI +58.91 
to +162.89), reslizumab MD +141.82 mL (95% CI +89.23 to +194.41); and omalizumab mean 
percentage change + 3.7% (95% CI 2.1% to 9.5%). There is low certainty of evidence that for 
patients with baseline eosinophils ≥300 cells/μl dupilumab may increase FEV1 compared to 
standard of care [MD +180mL (95% CI 110 to 250)]. 
Evidence of resource use and cost-effectiveness 
After screening 1884 hits and reviewing 36 full text articles, five economic evaluations were 
included (Figure 2). Two studies evaluated benralizumab (56,57), 1 dupilumab (57), 1 
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allergic patients (Table S4). Overall, the resources needed for adding the biological to standard 
asthma therapy are mainly the cost of the drug and its administration. The potential savings are 
related to decreased rate of hospitalisation, emergency department care, and primary care visits 
(Table S5). The evaluation of the cost-effectiveness of benralizumab shows important variation in 
ICER from 39,135 £/QALY (low certainty of the evidence) to 412,000$/QALY (moderate certainty 
of the evidence). The key driver for this difference is unclear since there is missing information in 
the Tikhonova et al report (Table S6). For dupilumab the reported ICER is 401,000 $/QALY in 
patients with ≥ 300 eosinophils/ μL (moderate certainty of the evidence). The results are uncertain 
for the utility estimates for the non-exacerbation health state for both the biological and standard 
of care asthma therapy, for the annual exacerbation rates for standard therapy and for the costs 
of chronic OCS use (Table S6). For mepolizumab the cost utility Markov model with low risk of 
bias (high quality study) reported an ICER/QALY value of 385,546 $ (low certainty of the 
evidence). There is also variation across patients. The most favourable ICER towards 
mepolizumab was 160,000 $ in the responder group of patients (Table S6). The reslizumab base-
case analyses demonstrate important variation across studies in terms of the cost-effectiveness 
results. The ICER/QALY varied from 23,081 $/ QALY (low certainty of the evidence) to 697,403 $ 
/ QALY (moderate certainty of the evidence). The key driver for this difference was the cost of 
reslizumab. The study not funded by industry (60) reported a higher cost of reslizumab 
(approximately 4,000 $ per month) compared to the study funded by industry (991 $ per month) 
(59). It has to be noted that there is a lack of proper studies to drive firm conclusions due to the 
heterogeneity of published studies. Furthermore, modelling cost-effectiveness studies considering 
direct and indirect costs applicable to each context are needed (Table S6). 
DISCUSSION 
Main findings
Our systematic review of efficacy shows high certainty for reducing the rate of severe asthma 
exacerbations for all the biologicals evaluated (benralizumab, dupilumab, mepolizumab, 
omalizumab, reslizumab) as add-on treatment for patients with severe uncontrolled eosinophilic 
asthma. The certainty is moderate for improving asthma control, QoL and lung function (FEV1) 
improvement, not reaching the MID. Only benralizumab, dupilumab and mepolizumab provided 
data about the use of OCS, showing a reduction in the daily dose of OCS compared to standard 
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The main reasons to downgrade the certainty of evidence were ROB, imprecision, and 
indirectness. Overall the included studies for the evidence of efficacy were of low ROB. Of note, 
all included studies were funded by industry and all showed positive results, which might raise 
concerns of on a potential sponsorship bias. Although short term safety data are reassuring, the 
rate of drug related AE was not comprehensibly reported, thus there is low to very low certainty 
for drug-related serious AE. With the exception of omalizumab there is scarce data on the 
efficacy of the evaluated biologicals for eosinophilic asthma in the paediatric population. With the 
exception of omalizumab and mepolizumab no data are available for long term safety, both in 
children and in adults.
The resources needed for adding the biological treatment to asthma standard therapy are mainly 
driven by the cost of the drug and its administration. With the approval of autoinjectors for most of 
these agents the costs for administration should decline. The potential savings are explained by 
the decreased rate of hospitalisation, emergency department care, and primary care visits. 
However, we cannot accurately assess the reductions in indirect costs such as improvements 
leading to improved work and school productivity and decreased absenteeism. The current SR of 
cost-effectiveness showed, for all the biologicals, an ICER per QALY value significantly above the 
willingness to pay threshold in most European countries (30,000 €/QALY).The certainty of the 
economic evidence is moderate derived from studies with low ROB but with important imprecision 
(large variations in the ICER values) and indirectness (differences in healthcare systems and year 
of conduction of the study), impeding both the transferability and generalization of the results. 
Additional publication bias might be envisaged. 
Current results in the context of previous results
Aligned with our results, previous SR of benralizumab, dupilumab, mepolizumab, omalizumab 
and reslizumab in severe asthma reported a reduction to approximately half of exacerbations, 
and an improvement in health related QoL scores, asthma control and FEV1 (61, 62, 63, 64, 65, 
66, 67, 68). However, there are some important differences that need to be mentioned. Previous 
mepolizumab SR allowed the inclusion of non-approved doses (64,65), while, the current SR 
included only licensed doses and routes of administration making the results more applicable to 
the daily practice. Another important difference is that the certainty of the evidence was assessed 
using the GRADE approach. In contrast with the previous reviews assessing only the ROB of the 
trials, the current SR evaluated the heterogeneity, imprecision and indirectness of the included 
evidence.  As an example, using the MID to assess for the imprecision, one can appreciate the 
clinical relevance of the change (i.e. asthma control, QoL and FEV1): although the change was 
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effect of all the biologicals across a comprehensive compilation of asthma related outcomes 
giving the clinicians a better perspective of the drug profile.
In contrast with our results, a SR of 8 benralizumab trials showed a lower risk of both AE (RR 
0.94; 95% CI 0.90–0.98) and serious AE (RR 0.82; 95% CI 0.68–0.98) (61). The possible 
explanation for this difference is that we limited our assessment to drug-related AE and excluded 
asthma worsening events, assessed solely as efficacy measures. 
Another review assessing the cost-effectiveness of mepolizumab for eosinophilic asthma showed 
that mepolizumab is cost-effective only when targeting specific subgroups with very severe 
asthma or by considerable price discounts. The key drivers of cost-effectiveness included day-to-
day health-related QoL, asthma-related mortality, acquisition price of the biological therapy, and 
time horizon. These results are similar to our evaluation for mepolizumab (69). 
Strengths and limitations 
The current systematic review has several strengths. An exhaustive evaluation of both desirable 
and undesirable effects of the use of biologicals, as well as their economic impact was performed. 
The compilation of critical and important asthma related outcomes provides a more 
comprehensive perspective of the drug profile. The current SR used rigorous methods including 
the GRADE approach to rate the certainty of the evidence, with transparent judgements about the 
quality of evidence. We included the most updated results available from the included RCTs and 
only considered licensed doses and routes of administration. We provided friendly tabulated 
summaries of findings using optimal presentation format for patients, clinicians and policy makers 
supporting all the stakeholders in their endeavour to formulate recommendations for the use of 
biologicals in severe uncontrolled eosinophilic asthma. 
There are several limitations. The basal exacerbation rate was used to estimate the absolute 
benefit for each drug/analysis. However, we did not perform a subgroup or sensitivity analysis 
based on that variable (basal exacerbation rate), as it was not pre-defined or requested in the 
protocol or during the systematic review.   The systematic review included only English language 
articles, however the risk of selection bias is probably small because we screened previous 
systematic reviews and the GDG included several international experts in the field, thus the 
possibility of missing results from non-English articles is unlikely.  We did not include 
observational studies that could have been informative for some of the outcomes with low or very 
low-quality evidence from RCTs (e.g. serious AE). We did not conduct a de novo economic 
analysis for the cost-effectiveness outcomes. However, we followed the global perspective on the 
use of biological treatment in different health systems, which may be useful for the decision of 
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eosinophilic asthma which restricted the number and scope of studies analysed, especially for 
omalizumab and dupilumab.
Implications for practice and research
All evaluated biologicals (benralizumab, dupilumab, mepolizumab, omalizumab, reslizumab) 
showed a significant improvement in critical and important related asthma outcomes such as 
exacerbation rate and for benralizumab, dupilumab and mepolizumab also an OCS dose 
reduction. However, the systematic review confirms the dissociated effect as these drugs have a 
modest effect on asthma control, quality of life and lung function. The health-economics and 
ICER analyses demonstrate above the willingness to pay threshold. Given the high cost of these 
drugs their use will probably be limited to very specific circumstances such as patients with 
severe uncontrolled asthma where the desired outcome is to decrease the exacerbation rate or 
the OCS use. In this context, panels are more likely to formulate conditional recommendations as 
opposed to strong. 
Although short term safety data is reassuring, more accurate reporting from clinical trials is 
warranted in combination with long-term safety and cost-effectiveness evaluations, including real-
world studies, registries and big data analysis. There is limited data available to support the 
efficacy and safety in the paediatric population (with the exception of omalizumab), highlighting 
the urgent unmet need for rigorous trials with biologicals in severe eosinophilic asthma in this 
population. Finally, the better understanding of predominant and personalized asthma endotypes 
and well-controlled head-to-head, industry-independent comparisons would provide useful data to 
better inform clinicians about choosing the right biologic for the right patient.
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Figure 1. Study flowchart for the selecting evidence for efficacy and safety of the 
























3441 records identified from databases 
(MEDLINE; EMBASE; CENTRAL) 





145 records assessed for eligibility 
(mepolizumab=30; reslizumab:25; 




   
 
135  full-text articles excluded 
Reasons: 
Different study design  
Different comparison of interest 
Diferent outcome of interest 
Different dose (Non-FDA approved ) 
Different population  
28 publications from 19 individual RCTs  
 
Mepolizumab: 7 publications from 3 RCTs 
Benralizumab: 6 publications from 3 RCTs 
Reslizumab:     8 publications from 5 RCTs 
Dupilumab:      3 publications from 3 RCTs 
Omalizumab:   4 publications from 5 RCTs 
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Number of studies (n= 1884) 
























Duplicate records removed (n= 
122) 
Records screened  
(n= 1762) 
 
Records excluded (n= 1728) 
 No relevant to biologic 
treatment for asthma 
patients. 
Full-text articles assessed for 
eligibility (n= 36) 
Excluded at full text level: 31 
 Non-eosinophilic patients: 20 
 Conference abstract: 3 
 Health outcomes not 
reported: 3 
 Systematic review used as 
source of primary studies: 2 
 No economic evaluation: 2 












Studies identified only 
through manual revision of 
the references of the 










Table 1. Summary of the characteristics of the included studies evaluating clinical efficacy of benralizumab, mepolizumab, omalizumab and 












Number of patients exposed (N) 
Control 
Benralizumab      






Severe, uncontrolled asthma  
(N=1205) 
Benralizumab: 30 mg SC Q8W 
(N=398) 











Severe, uncontrolled asthma  
(N= 1306) 
Benralizumab: 30 mg SC Q8W 
(N=441) 












Severe uncontrolled asthma 
receiving daily OCS (N=220) 
Benralizumab 30mg SC Q8W (N=73) 





Dupilumab      










Dupilumab 200 mg SC Q2W (loading 
dose, 400mg) (N=631) 
 
Dupilumab 300 mg SC Q2W (loading 
























Moderate to severe, 




Dupilumab 200 mg SC Q2W 
Dupilumab 300 mg SC Q2W 
Dupilumab 200 mg SC Q4W 
Dupilumab 300 mg SC Q4W 
SOC 
 


















Severe eosinophilic asthma 
receiving daily OCS  
(N=135) 











Severe eosinophilic asthma 
(N=576) 
75-mg IV Q4W (N-191) 













Severe eosinophilic asthma 
(N=551)  
100 mg SC Q4W (N=274) 
SOC 
 
Omalizumab      
Casale 2018 (51) 
16  
 




SC Q2W or Q4W at a dose 
calculated based on body weight and 
baseline serum IgE levels (150 mg or 
300 mg Q4W or 225 mg, 300 mg, or 






Hanania 2013 (48) 
 
48 
44 ± 15 
12-75 
Uncontrolled severe persistent 
allergic asthma (N=850) 
Subgroup high blood 
eosinophils (N=414) or high 
FeNO (N=101) 
Dose determined by the European 
omalizumab dosing table, ensuring a 
minimum omalizumab dose of 0.008 
mg/kg/IgE (IU/mL) Q2W or a 






Sorkness 2013 (49)  
 
48 
10.7 ± 3.6 
6-20 
Moderate to severe persistent 
allergic asthma  
Subgroup with high FeNO 
(N=155) 
Dose determined the expanded  FDA 
dosage table, ensuring a minimum 





Busse 2013 (50) 28 12-75  
Patients with atopic asthma 
Subgroup with eosinophilic 
asthma (N=51) 
Dose determined by the European 
omalizumab dosing table, ensuring a 
minimum omalizumab dose of 0.008 
mg/kg/IgE (IU/mL) Q2W or a 

























eosinophilic asthma (N=311) 
 
 








44.9 ± 13.94 
(18-75) 
Inadequately controlled 
eosinophilic asthma (N=106) 
 
 












eosinophilic asthma (N=953) 












Inadequately controlled asthma 
 
Subgroup with baseline 
eosinophils ≥ 400 cells/μL 
(n=96) 












































addition to SOC 
Lifetime SOC Lifetime, US 
health care 
perspective. 
Societal in the 
sensitivity 
analysis. 

















addition to SOC 
Lifetime SOC Lifetime, UK 
NHS 
perspective. 
Societal in the 
sensitivity 
analysis. 
Not Reported   QALY not 
reported  
 
















addition to SOC 
Lifetime SOC Lifetime, US 
health care 
perspective. 




(2018 US Dollars) 
1.51 QALY 
 
464,000 $ / 
QALY 












addition to SOC 
Lifetime SOC Lifetime, health 
system 
589,941 $ 
(2014 US Dollar) 
1.53 QALY 
 
385,546 $ / 
QALY 











































addition to SOC 
Lifetime SOC Lifetime, 
societal 
119,394 $ 
(2018 US Dollars) 
5.17 QALY 
 










addition to SOC 
5-year SOC 5-year, societal 24,404 $ 
(2017 US Dollar) 
0.035 QALY 
 
697,403 $ / 
QALY 















Table 3: Summary of findings for Benralizumab compared to standard of care for eosinophilic asthma 
Outcomes 
№ of participants 
(studies) 
Follow-up (range) 





Anticipated absolute effects 
Risk with standard of care 
Risk difference with 
benralizumab 
Exacerbations  




(3 RCTs) 39,40,,41 
28 to 56 weeks 
⨁⨁⨁⨁ 
HIGH 3,a,b 
Rate ratio 0.53 
(0.39 to 0.72) c,d 
1500 exacerbations per 
1000 patients per year   
705 fewer exacerbations 
per 1.000 patients per 
year 
(915 fewer to 420 fewer) 
Asthma Control  
Assessed with ACQ-6 score 
between-group-difference at the 
end of the study 
 
1373 
(3 RCTs) 39,40,,41 
28 to 56 weeks 
⨁⨁⨁⨁ 
HIGH 3,4,b,e,f 
-   mean difference - 0.26  
(- 0.46 to - 0.07 fewer) c,g 
Quality of life 
Assessed with Asthma Quality of 




(3 RCTs) 39,40,,41 
28 to 52 weeks 
⨁⨁⨁⨁ 
HIGH 3,6,b,j,k 
-   
mean difference+ 0.23 
higher 
(+0.11 to +0.36) c 
Any drug related adverse event 
(AE)  
Assessed with number of events 
 
478 




Rate ratio 1.41 
(0.87 to 2.27)  
105 per 1.000  
43 more per 1.000 
(14 fewer to 133 more)  
Any serious adverse event 
(SAE) unrelated to asthma 
exacerbation  
Assessed with number of events 
 
148 




Rate ratio 0.56 
(0.22 to 1.44)  
147 per 1.000  
65 fewer per 1.000 
(114 fewer to 65 more)  
Decrease in OCS use  
Assessed with reduction in daily 
OCS dose of ≥50% 
 
148 




Rate ratio 1.76 
(1.26 to 2.47)  
373 per 1.000  
284 more per 1.000 
(97 more to 549 more)  
Lung function   
Assessed with pre-bronchodilator 
FEV1 (mL) between-group-
difference at the end of the study 
 
1370 
(3 RCTs) 39,40,,41 




-   
mean difference +140 mL  
(+90 to +190 higher) c 
Rescue medication use  
Asssessed with puffs/day 











Table 3: Summary of findings for Benralizumab compared to standard of care for eosinophilic asthma 
Outcomes 
№ of participants 
(studies) 
Follow-up (range) 





Anticipated absolute effects 
Risk with standard of care 
Risk difference with 
benralizumab 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the 
intervention (and its 95% CI).  
GRADE Working Group grades of evidence 
High certainty: High confidence that the true effect lies close to that of the estimate of the effect 
Moderate certainty: Moderate confidence in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is 
substantially different 
Low certainty: Limited confidence in the effect estimate: The true effect may be substantially different from the estimate of the effect 
Very low certainty: Little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
Explanations 
a. Statistically significant (I2=65%) but probably unimportant heterogeneity.  
b. All included studies were funded by industry, and all showed positive results. No industry-independent observational or randomized studies were identified to contrast results. Therefore, 
the quality of the evidence was downgraded for potential publication bias (70).  
c. The pooled data were assessed at 28 weeks (41) and at 48-52 weeks (71). Goldman 2017 included patients aged 12-17 years old.  
d. In the current systematic review 2 studies reporting the effect on exacerbation leading to emergency room visits or hospitalizations were also included. The pooled risk ratio was 0.24 (95% 
CI 0.03-1.72) (see full text report).  
e. Statistically significant (I2=61%) but probably unimportant heterogeneity.  
f. The minimal important difference (MID) for ACQ-6 is 0.5 points (35).  
g. In the current systematic review 3 studies reporting the effect on total asthma control score change were also included. The pooled mean difference was -0.19 (95CI% -0.31 to -0.08), see 
full text report.  
h. Quality of the evidence was downgraded because FEV1 is considered a surrogate outcome for asthma control, with a variable correlation with asthma symptoms (72).  
i. The panel agreed that minimal important difference for FEV1 is 0.20 L.  
j. Statistically significant (I2=55%) but probably unimportant heterogeneity.  
k. For AQLQ(S)+12 the MID is 0.5 (37)  
















Table 4: Summary of findings of  Dupilumab compared to standard of care for eosinophilic asthma 
Outcomes 









Anticipated absolute effects 
Risk with standard of 
care 
Risk difference with 
dupilumab 
Exacerbations  




(3 RCTs) 42,43,44 




0.44(0.32 to 0.59)  
1570 exacerbations per 
1000 patients per year   
894 fewer exacerbations 
per 1000 patients per year 
(1086 fewer to 655 fewer)c  
Asthma control  
assessed with: Asthma Control 
Questionnaire -5 
Scale from: 1 to 5 
507 






-   
mean difference - 0.48  
(-0.88 lower to - 0.09)  
Quality of life 
Assessed with asthma Quality of 
Life Questionnaire  
Scale from: 1 to 7 
958 
(2 RCTs) 43,44 





-   
mean difference + 0.42 
higher 
(+0.25 to +0.59)  
Treatment-related adverse events 
(AE) 
Assessed with number of events 
264 







(0.88 to 1.13)  
794 per 1.000  
0 fewer per 1.000 
(95 fewer to 103 more)  
Treatment-related serious 
adverse events (SAE) 
Assessed with number of events 
264 





(0.60 to 3.54)  
59 per 1.000  
27 more per 1.000 
(24 fewer to 149 more)  
Decrease in OCS dose  
Assessed with percentage of 
reduction compared to baseline 
150 




-   
mean difference - 29.4 %  
(-43.23 to -15.57 )  
Lung function  
Assessed with FEV1 in mL 
1030 
(3 RCTs) 42,43,44 




-   
mean difference + 180 mL  
(+110 to +250)  
Fraction of exhaled nitric oxide  
Assessed with mean % change 
(ppb) from baseline 
150 





-   
mean difference - 40.11 %  
(-78.68 to -1.55)  
Rescue medication use  
Assessed with puffs/day 
 
143 
(1 RCT) 42 




-   
mean difference - 0.56 
puff/day  
(-2.28 to +1.16)  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the 











Table 4: Summary of findings of  Dupilumab compared to standard of care for eosinophilic asthma 
Outcomes 









Anticipated absolute effects 
Risk with standard of 
care 
Risk difference with 
dupilumab 
GRADE Working Group grades of evidence 
High certainty: High confidence that the true effect lies close to that of the estimate of the effect 
Moderate certainty: Moderate confidence in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that 
it is substantially different 
Low certainty: Limited confidence in the effect estimate: The true effect may be substantially different from the estimate of the effect 
Very low certainty: Little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect 
Explanations 
a. All included studies had a high risk of selective reporting bias (42,43,44). However, the evidence quality was not downgraded because most of the outcomes of interest for our analysis 
were reported.  
b. All included studies were founded by industry and the same company (Sanofi and Regeneron Pharmaceuticals), and all showed positive results. No industry-independent observational or 
randomized trials were identified to contrast the results. Therefore, the quality of the evidence was downgraded for potential publication bias (70)  
c. Two studies (Rabe 2018, Wenzel 2016) assessed exacerbations at 24 weeks, and Castro2018 at 52 weeks.  
d. The quality of the evidence was downgraded because FEV1 is considered a surrogate outcome of asthma control, with a variable correlation with asthma symptoms (72).  
e. The panel agreed that minimal important difference (MID) for FEV1 is 0.20 L and considered the effect as imprecise.  
f. The panel agreed that minimal important difference (MID) for FEV1 is 0.20 L and thus the effect was considered as imprecise.  
g. Downgraded because the effect of dupilumab is beneficial but the lower side of the CI is less than the MID( 0.5 points). (37)  
h. Downgraded because the effect of dupilumab is beneficial but the lower side of the CI is less than the MID( 0.5 points). (37)  
i. Downgraded because FeNO is not consistently considered a good surrogate of eosinophilic inflammation (73,74)  
j. From one visit to the next a change greater than 20% for basal values over 50 ppb or more than 10 ppb for basal values lower than 50 ppb may indicate significant response (38).  
k. Downgraded because the effect may both be beneficial and harmful.  
l. The MID for rescue medication use is a reduction by 0.81 puffs/day (35).  


















Table 5: Summary of findings of mepolizumab compared to standard of care for eosinophilic asthma 
Outcomes 
№ of participants 
(studies) 
Follow-up (range) 





Anticipated absolute effects 
Risk with standard of 
care 
Risk difference with 
mepolizumab 
Exacerbations 
Exacerbation rate ratio  
Assessed witt the annualized rates of 
asthma exacerbations  
 
1071 
(3 RCTs) 45,46,47 
24 to 32 weeks 
⨁⨁⨁⨁ 
HIGH 4,5,a,b,c 
Rate ratio 0.49 
(0.38 to 0.66)  
1700 exacerbations per 
1000 patients per year   
870 fewer exacerbations per 
1000 patients per year 
(592 fewer to 1079 fewer) 
Exacerbations leading to 
hospitalisation 
Assessed with the annualized rate of 
asthma exacerbations leading to 
hospitalisation 
(2 RCTs) 45,47 
24 to 32 weeks 
⨁⨁⨁⨁ 
HIGH 4,5,a,c,d 
Rate ratio 0.30 
(0.13 to 0.71)  
100 exacerbations per 
1000 patients per year 
70 fewer exacerbations per 
1000 patients per year 
(29 fewer to 87 fewer)  
Asthma control 
Assessed with: ACQ-5 score 
between-group-difference at the end 
of the study 
Scale from: 0 to 6 9,j 
912 




-   
mean difference - 0.43  
(- 0.56 to - 0.31)  
Quality of life 
Assessed with  St. George's 
Respiratory Questionnaire between-
group-difference at the end of the 
study 
1045 
(3 RCTs) 45,46,47 




-   
mean difference - 7.14  
(- 9.07 to - 5.21)  
Treatment-related adverse events 
(AE) 
Assessed with number of events 
1071 
(3 RCTs) 45,46,47 
⨁⨁⨁⨁ 
HIGH 4,5,c 
Rate ratio 1.35 
(1.01 to 1.80)  
796 per 1.000  
279 more per 1.000 
(8 more to 637 more)  
Treatment-related serious adverse 
events (SAE) 
Assessed with number of events 
385 




Rate ratio 0.98 
(0.06 to 15.63)  
5 per 1.000  
0 fewer per 1.000 
(-5 fewer to 77 more)  
Lung function 
assessed with pre-bronchodilator 
FEV1 (mL) between-group-difference 
at the end of the study 
1043 
(3 RCTs) 45,46,47 




-   
mean difference +110.9 mL  
(+58.91 to +162.89)  
Lung function 
assessed with AM peak expiratory 
flow (PEF) 
936 
(2 RCTs) 77 
24 weeks 6,g 
⨁⨁◯◯ 
LOW 4,5,c,h,i 
-   
mean difference +22.46  











Table 5: Summary of findings of mepolizumab compared to standard of care for eosinophilic asthma 
Outcomes 
№ of participants 
(studies) 
Follow-up (range) 





Anticipated absolute effects 
Risk with standard of 
care 
Risk difference with 
mepolizumab 
Rescue medication use 
assessed with puffs/day 
(1 RCT) 45 
21 to 24 weeks o 
⨁⨁⨁⨁ 
HIGH 4,5,c 
-   
mean difference -0.1 puff/day  
(-0.35 to +0.15)  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).  
GRADE Working Group grades of evidence 
High certainty: High confidence that the true effect lies close to that of the estimate of the effect 
Moderate certainty: Moderate confidence in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different 
Low certainty: Limited confidence in the effect estimate: The true effect may be substantially different from the estimate of the effect 
Very low certainty: Little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect 
Explanations 
a. Two of three studies had a high risk of attrition bias (45,47). Modified intention-to-treat analysis was conducted (i.e. patients were analysed as treated, not as randomized).  
b. Probable unimportant heterogeneity  
c. Included studies were all funded by industry, and all showed positive results. We identified two industry-independent observational trials that showed similar effects with our meta-analysis 
(76,77).  
d. Mean rates of exacerbation requiring hospitalization across studies were very low (i.e. from 0.02 to 0.10 exacerbations requiring hospitalization per person-year), both in the placebo and 
intervention arms  
e. The panel agreed that minimal important difference (MID) for FEV1 is 0.20 L 
f. Downgraded because FEV1 is considered a surrogate outcome of asthma control of symptoms, with a variable correlation with asthma symptoms (72).  
g. The MID of PEF is 18.8 L/min (35)  
h. Potential attrition bias because PEF baseline values reported in the primary publication (47) differed from values reported in post-hoc analysis publication (77)  
i. Downgraded because the lower CI boundary crosses the MID threshold  
j. 0.5 points is the minimal important difference for the Asthma Control Questionnaire (ACQ-5 score) (37)  
k. >-4.0 was considered the threshold for the MID for quality of life measured with the St.George's Respiratory Questionnaire (36) 
l. The St.George's Respiratory Questionnaire SGRQ is not a disease-specific questionnaire for asthma  
m. Findings from only 1 RCT available. Downgraded due to publication bias  
n. Very few numbers of events per arm  















Table 6: Summary of findings of  Omalizumab compared to standard of care for eosinophilic asthma 
Outcomes 
№ of participants 
(studies) 
Follow-up (range) 





Anticipated absolute effects 
Risk with standard of 
care 
Risk difference with 
omalizumab 
Exacerbations 
Assessed with annual asthma exacerbations rate 
 
779 
(3 RCTs) 48,50,51 
16 to 48 weeks 
⨁⨁⨁⨁ 
HIGH 4,a,b 
Rate ratio 0.56 
(0.40 to 0.77)  
660 exacerbations per 
1000 patients per year   
290 fewer exacerbations 
per 1.000 patients per year 
(396 fewer to 152 fewer)  
Asthma Control 
Assessed with Total Asthma Symptoms Score  
414 




-   
mean difference - 0.16  
(- 0.51 to +0.19) e,f 
Quality of Life  
Assessed with Asthma Quality of Life 
Questionnaire 
414 




-   
mean difference + 0.13  
(-0.11 to + 0.37) l 
Any adverse event  
Assessed with number of events 
 
414 




Rate ratio 1.01 
(0.91 to 1.11) 
794 per 1.000  
8 more per 1.000 
(71 fewer to 87 more)  
Lung Function  
Assessed with % pre-bronchodilator FEV1 
between-group-difference at the end of the study 
 
(2 RCTs) 48,50 
24 weeks to 48 weeks 
⨁⨁⨁◯ 
MODERATE 4,5,a,b,g,h,i 
-   
mean difference + 3.7 %  
(-2.1 lower to + 9.5) j,k 
Rescue medication use  
Assessed with puffs/day change from baseline  
414 




-   
mean difference - 0.34  
(-0.83 to +0.15) 6,m,n 
GRADE Working Group grades of evidence 
High certainty: High confidence that the true effect lies close to that of the estimate of the effect 
Moderate certainty: Moderate confidence in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different 
Low certainty: Limited confidence in the effect estimate: The true effect may be substantially different from the estimate of the effect 
Very low certainty: Little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect 
Explanations 
a. Information of included studies from non-predefined subgroup analysis.  
b. Included studies were all funded by industry, and all showed positive results. We identified one industry-independent observational trial that showed similar effects with our meta-analysis 
(78).  
c. The total asthma symptoms score is an unvalidated scale.  
d. The effect may both be harmful or beneficial.  
e. Data from subgroup of patients with blood eosinophil count ≥ 260/ul. This study also reported total asthma symptoms score for the subgroup of FeNO ≥ 24ppb, the mean difference is -0.25 











f. In the current systematic review we also included one study (49) reporting the effect on the symptom days over the previous 2 weeks at 48 weeks follow up, the mean difference is -0.45 
(p=0.05) (see full text report).  
g. Statistically significant (I2=70%), but probably unimportant heterogeneity.  
h. Downgraded because FEV1 is considered a surrogate outcome of asthma control of symptoms, with a variable correlation with asthma symptoms (72)  
i. The panel agreed that minimal important difference (MID) for FEV1 is 0.20 L  j. Population with different threshold of eosinophil counts across the studies: ≥ 200 cells/µl (51), ≥ 300 cells/µl 
(50) and ≥ 260 cells/µl (48).  
k. One of the included studies (48) also reported the effect on FEV1 % change for a population with FeNO ≥ 24 ppb, the LS mean difference is 3.20 (CI 95% -0.74 to 0.27). The pooled effect 
evaluated at 48 weeks (48) and 24 weeks (50).  
l. Data from subgroup of patients with blood eosinophil count ≥ 260/ul. This study also reported AQLQ for the subgroup of FeNO ≥ 24ppb , the mean difference is 0.37 (CI 95% 0.01 to 0.73).  
m. This study also reported the effect on rescue medication use for the subgroup of FeNO ≥ 24 ppb, the mean difference is -0.49 (CI 95% -0.88 to -0.11).  
n. The MID for rescue medication use is 0.81 puffs/day (35).  
References 
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Table 7: Summary of findings of  Reslizumab compared to standard of care for eosinophilic asthma 
Outcomes 
№ of participants 
(studies) 
Follow-up (mean or range) 





Anticipated absolute effects 
Risk with standard of 
care 
Risk difference with 
reslizumab 
Exacerbations  
Assessed with annualised rate of asthma 
exacerbationsa 
1059 
(3 RCTs) 1,2 
52 weeks  
⨁⨁⨁⨁ 
HIGH 3,b 
Rate ratio 0.46 
(0.37 to 0.58) c 
1800 exacerbations per 
1000 patients per year   
972 fewer exacerbations 
per 1000 patients per 
year 
(1134 fewer to 756 fewer)  
Exacerbations leading to ER visit or 
hospitalisation 
Assessed with annualised rate of asthma 
exacerbations  
953 




Rate ratio 0.67 
(0.39 to 1.17)  
120 exacerbations per 
1000 patients per year   
40 fewer exacerbations 
per 1000 patients per 
year  
(73 fewer to 20 more) 
Asthma control 
Assessed with Asthma Control Questionnaire-7 
Scale from: 0 to 6 
1359 
(5 RCTs) 1,2,4,5 
15 weeks to 16 weeks 
⨁⨁⨁⨁ 
HIGH 3,8,b,h 
-   
mean difference - 0.25  
(- 0.34 to - 0.16)  
Quality of life 
assessed with Asthma Quality of Life 
Questionnaire 
Scale from: 1 to 7 
1153 
(3 RCTs) 1,4 
15 to 16 weeks 
⨁⨁⨁⨁ 
HIGH 3,10,b,k 
-   
mean difference + 0.17  
(+0.08 to + 0.25) l 
Treatment-related adverse events  
Assessed with number of events 
1269 
(4 RCTs) 1,2,4 
15 to 52 weeks 
⨁⨁⨁◯ 
MODERATE 3,b,o 
Rate ratio 1.18 
(0.89 to 1.56) p 
125 per 1.000  
22 more per 1.000 
(14 fewer to 70 more) p 
Treatment-related serious adverse events  
Assessed with number of events 
 
1269 
(4 RCTs) 1,2,4 
15 to 52 weeks p 
⨁⨁◯◯ 
LOW 3,b,q 
Rate ratio 4.71 
(0.54 to 41.31)  
0 per 1.000  
0 fewer per 1.000 
(0 fewer to 0 fewer)  
Decrease in inhaled corticosteroid (ICS) and 
oral corticosteroid (OCS) dose  
0 studies  -  -  -  -  
Lung function  
Assessed with: FEV1 in mL 
 
1360 
(5 RCTs) 1,2,4,5 
15 to 16 weeks 
⨁⨁⨁◯ 
MODERATE 3,6,7,b,e,f 
-   
mean difference +141.82 
mL  
(+89.23 to 194.41) g+ 
Rescue medication use 
Assessed with puffs/day 
1251 




-   mean difference - 0.24  











Table 7: Summary of findings of  Reslizumab compared to standard of care for eosinophilic asthma 
Outcomes 
№ of participants 
(studies) 
Follow-up (mean or range) 





Anticipated absolute effects 
Risk with standard of 
care 
Risk difference with 
reslizumab 
Asthma symptoms 
Assessed with: Asthma Symptom Utility Index  
Scale from: 0 to 1 
 
1157 
(3 RCTs) 1,4 
16 weeks to 16 weeks 
⨁⨁⨁⨁ 
HIGH 3,9,b,j 
-   
mean difference +0.05  
(+0.03 to +0.07 higher)  
Changes in blood eosinophil counts 
Assessed with: cells/µL 
 
1264 
(4 RCTs) 1,2,4 
15 weeks to 16 weeks 
⨁⨁⨁◯ 
MODERATE 3,11,b,m 
-   
mean difference - 468.58  
(-494.92 to - 442.24)  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).  
GRADE Working Group grades of evidence 
High certainty: High confidence that the true effect lies close to that of the estimate of the effect 
Moderate certainty: Moderate confidence in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different 
Low certainty: Limited confidence in the effect estimate: The true effect may be substantially different from the estimate of the effect 
Very low certainty: Little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect 
Explanations 
a. Clinically significant asthma exacerbations: episodes of asthma worsening with systemic corticosteroids for 3 or more days, a two-times increase in the dose of either inhaled 
corticosteroids or the need for asthma-related emergency treatment.  
b. All included studies were funded by industry, and all showed positive results. No industry-independent observational or randomized studies were identified to contrast the results. 
Therefore, the quality of the evidence was downgraded for potential publication bias (70).  
c. The pooled effect of risk ratio was assessed at 15 weeks (52) and the rate ratio was evaluated at 52 weeks (53)  
d. Downgraded because the absolute effect includes both potential clinically meaningful benefits and harms.  
e. Downgraded because FEV1 is considered a surrogate outcome of asthma control of symptoms, with a variable correlation with asthma symptoms (72).  
f. The panel agreed that minimal important difference (MID) for FEV1 is 0.20 L g. Castro 2015 also assessed FEV1 at 52 weeks, the mean difference from baseline was 122.28 mL(45.54, 
199.02). We also included 3 studies (52,54, 55) reporting FVC (mL), the pooled mean difference was 205.94 (88.69, 323.19); see full text report.  
h. MID for ACQ-7 is 0.5 points (Juniper 2005).  
i. Castro 2015 also assessed ACQ-7 at 52 weeks, the mean difference from baseline of ACQ-7 was -0.25 (-0.34, -0.16), see full text report.  
j. MID for the Asthma symptoms utility index is an increase of 0.09 points (79).  
k. MID of AQLQ is 0.5 points (37).  
l. Castro 2015 also assessed AQLQ at 52 weeks, the mean difference from baseline was 0.29 (0.18, 0.41), see full text report.  
m. Reduction of blood eosinophil counts is a surrogate endpoint and not validated as a valuable outcome for monitoring asthma therapy (80).  
n. MID for rescue medication use is a reduction by 0.81 puffs/day (35).  
o. The effect may both be harmful or beneficial.  
p. Data regarding this outcome was extracted from www.clinicaltrials.gov for ref.52 and ref.53 
q. Very few events in both arms, thus it is not possible to estimate precisely the effect size between arms
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